



HAL
open science

Changes in S100B and troponin levels in a fetal sheep model of worsening acidosis

Yasmine Ould Hamoud, J. D. Pekar, Elodie Drumez, Laure Lacan, Patrice Maboudou, Julien de Jonckheere, Laurent Storme, Veronique Debarge, Dyuti Sharma, Charles Garabedian, et al.

► **To cite this version:**

Yasmine Ould Hamoud, J. D. Pekar, Elodie Drumez, Laure Lacan, Patrice Maboudou, et al.. Changes in S100B and troponin levels in a fetal sheep model of worsening acidosis. *European Journal of Obstetrics & Gynecology and Reproductive Biology*, 2021, *European Journal of Obstetrics & Gynecology and Reproductive Biology*, 264, p. 173-177. 10.1016/j.ejogrb.2021.06.042 . hal-04540490

HAL Id: hal-04540490

<https://hal.univ-lille.fr/hal-04540490v1>

Submitted on 22 Jul 2024

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution - NonCommercial 4.0 International License

1 **Changes in S100B and troponin levels in a fetal sheep model of worsening acidosis.**

2

3 Yasmine Hamoud¹, Jean David Pekar², Elodie Drumez³, Laure Lacan⁴, Patrice Maboudou²,

4 Julien De Jonckheere⁵, Laurent Storme⁶, Véronique Houfflin-Debarge¹, Dyuti Sharma⁷,

5 Charles Garabedian¹, Louise Ghesquière¹

6 ABBREVIATIONS

7 HIE: hypoxic-ischemic encephalopathy

8 HI: hypoxia-ischemia

9 FHR: fetal heart rate

10 c-TnT: cardiac troponin T

11 UCO : umbilical cord occlusion

12 ABSTRACT

13 Background - S100B and cardiac troponin T (c-TnT) are relevant biomarkers at birth of
14 hypoxic-ischemic encephalopathy (HIE) and myocardial ischemia secondary to metabolic
15 acidosis during labor, respectively. The purpose was to assess in-utero changes in S100B and
16 c-TnT levels in an experimental model of labor-like acidosis.

17 Methods - Repeated umbilical cord occlusions (UCOs) in ten experiments were performed in
18 mild (phase A, 1 UCO/5 mn), moderate (phase B, 1 UCO/3 mn), and severe (phase C, 1
19 UCO/2 mn) period. The experiments were stopped if arterial pH reached 6.90.

20 Results - UCOs resulted in fetal acidosis with pH dropping to 6.99 ± 0.13 . When compared
21 to the baseline period fetal S100B increased between phases A and B ($7\% \pm 4$ vs $17\% \pm 13$, p
22 $= 0.030$) and between phases A and C ($7\% \pm 4$ vs $24\% \pm 8$, $p < 0.001$). Fetal c-TnT serum
23 levels increased during occlusions: 102 ng/L (58-119) in phase A, vs 119 ng/L (103-198) in
24 phase B vs 169 ng / L (128-268) in phase C ($p < 0.05$, for all). When compared to the baseline
25 control period, fetal Δ cTnT was significantly modified throughout UCO series: 5.0% (-3; 45)
26 in phase A, 51% (4; 263) in phase B, and 77% (56.5; 269) in phase C ($p < 0.05$ for all).

27 Conclusions - S100B and c-TnT increased when fetal acidosis occurred, which reflects the
28 potential neurological damage and fetal cardiovascular adaptation.

29

30

31 Key words: S100B, cardiac troponin T, acidosis, fetal sheep, biomarker, perinatal asphyxia

32 Introduction

33 Uterine contractions can reduce uteroplacental perfusion by up to 60% leading to progressive
34 fetal hypoxia (1). At term, healthy fetuses are able to withstand this transient hypoxia by
35 reducing oxygen consumption and redirecting the oxygenated blood flow to critical organs
36 (heart, brain, and adrenals) through activation of the peripheral chemoreflex (2,3). Providing
37 there is adequate time for fetoplacental reperfusion between contractions, this mechanism
38 protects fetuses from severe and irreversible hypoxic injuries. However, some fetuses
39 develop intrapartum metabolic acidemia which remains a leading cause for neonatal
40 complications, such as stillbirth, hypoxic-ischemic encephalopathy (HIE) and cerebral palsy.
41 In the past decade, tissue-specific biochemical damage markers, such as S100B and cardiac
42 troponin T (c-TnT) have been examined in umbilical cord blood at birth (4,5). The calcium-
43 binding S100B protein is mainly concentrated in the glial cells of the nervous system. S100B
44 has been presented as the most promising neurobiomarker in neonates with birth asphyxia
45 (6). The increase in S100B concentration in body fluids, such as cerebrospinal fluid, blood, or
46 urine, is a reliable marker of brain damage following asphyxia in neonates (7). The advanced
47 hypothesis is that in case of brain lesions, some of the S100B released by the affected tissue
48 could spread through the blood-brain barrier into the systemic circulation. In neonates
49 suffering from severe forms of HIE, S100B is elevated in umbilical cord blood samples at
50 birth and is associated with the severity of disease and risk of further neurodevelopmental
51 sequelae (8). Cardiac troponin T is commonly used as a myocardial ischemia marker in both
52 adults and infants. Studies have shown that in perinatal asphyxia, it could also be a strong and
53 useful predictor of myocardial injury in birth asphyxia and HIE (9). Costa et al. reported that
54 asphyxiated neonates had higher c-TnT levels associated with decreased cardiac output when
55 compared with control healthy newborns (10). Yet, the degree of prematurity, fetal weight
56 and type of delivery may complicate the assessment (11).

57 The in-utero levels of these biomarkers in response to worsening acidosis have still not been
58 described. The purpose of this study was to assess the changes in S100B and c-TnT levels in
59 both fetal and maternal serums in an experimental model of severe labor-like acidosis.

60 Materials and methods

61 *Surgical preparation*

62 Near-term pregnant sheep (Ile de France, INRA, Val de Loire, France) with a gestational age
63 of 124 ± 1 days (term = 145 days) underwent our surgical procedure, as described previously
64 (12,13). If an ewe had multiple fetuses, only one was instrumented and included in the
65 experiment.

66 For anesthesia, ewes had a vascular infusion of 500 mL of Ringer lactate, then a
67 premedication of 0.3 mL intravenous Sedaxylan (xylazine 20mg/ml; Dechra, The
68 Netherlands). Induction was made with isoflurane 5% before intubation, and anesthesia was
69 maintained with soflurane 2% (14). After maternal laparotomy and hysterotomy, catheters
70 (4-Fr diameter; Arrow, Reading, PA, USA) were placed in the fetal axillary arteries. The
71 catheter tips were advanced to the ascending aorta. Four electrocardiogram (ECG) electrodes
72 (Mywire 10; Maquet, Rastatt, Germany) were placed on the fetal intercostal muscles to
73 record fetal ECG. An inflatable silicone occluder (OC16; In Vivo Metric, Healdsburg, CA,
74 USA) was placed around the umbilical cord and the volume of saline solution required to
75 achieve complete occlusion was determined.

76 The ewes were acclimatized to the experiment room 1 hour a day in the presence of the main
77 investigators in charge of carrying out the experiments.

78 The experimental protocol began 4 days after the surgery. After 1 hour of baseline period,
79 repetitive umbilical cord occlusions (UCOs) were performed by injecting an isotonic solution
80 into the occluder to obtain a total occlusion for 1 minute. The protocol was divided into three
81 periods of 1 hour each, as described previously by Prout et al (15). During the mild phase,
82 UCOs were repeated every 5 minutes (phase A). During the second phase (phase B), the
83 rhythm was of one UCO every 3 minutes. Finally, the last period (phase C) consisted of one

84 UCO every 2 minutes. The protocol was stopped before the end of phase C if pH reached
85 6.90 or below.

86 Euthanasia was performed either at the end of the experimental procedure, or in cases of
87 spontaneous labor, in-utero fetal death, or death during surgery, by intravenous injection of 6
88 mL/50 kg of T61 (1 mL contains embutramide 200mg + mebezonium 26.92 mg + tetracaine
89 4.39 mg, MSD France, Courbevoie, France) (14).

90 *Monitoring parameters and measurement techniques*

91 Arterial blood gas parameters were measured with the i-STAT 1 blood analyzer (i-STAT 1
92 System; Abbott Point of Care, Inc, Princeton, NJ, USA) using CG4+ cartridges at specific
93 time points. Hemodynamic data were recorded continuously throughout the experiment. The
94 fetal arterial and intra-amniotic catheters were connected to pressure sensors (Pressure
95 Monitoring Kit 1; Baxter, Guyancourt, France) that were connected to a blood pressure
96 monitor (Monitor Merlin, Hewlett Packard, Palo Alto, CA, USA). The arterial blood pressure
97 (ABP) was measured from the blood pressure phasic signal and referenced to the intra-
98 amniotic pressure (IAP) (calculated ABP = observed ABP - observed IAP). Biochemical
99 assays were performed from serum on a Cobas 8000 module e601 (Roche, Basel,
100 Switzerland) using the electrochimiluminescence method. S100B and c-TnT were measured
101 in both the mother (M S100B or M c-TnT) and fetus (F S100B or F c-TnT). Collected blood
102 samples were centrifuged at 3500 g for 10 minutes and supernatant stored at - 80° C until
103 assessment. Delta S100B and c-TnT were defined as the difference in percentage of increase
104 or decrease compared to the baseline control period (F Δ S100B, M Δ S100B and F Δ c-
105 TnT). During the baseline period, every 20 minutes during each UCO phase and at the end of
106 each UCO phase, a 5-minute period with no UCO was observed to assess fetal
107 hemodynamics, mean arterial blood pressure (Mean ABP), fetal heart rate (FHR), and arterial
108 blood gases. We analyzed the data from the baseline period and from the 5-minute intervals

109 in between each UCO phases where an additional blood sample was performed for S100B
110 and c-TnT dosages.

111 *Statistics*

112 The gaussian variables are described in terms of mean and standard deviation and non-
113 Gaussian variables in terms of median and interquartile range. The normality of the
114 numerical variables was verified graphically and tested using the Shapiro-Wilk test.
115 Parameter changes during the occlusion phases were evaluated using a mixed linear model
116 with an unstructured covariance structure to account for the correlation between repeated
117 measures and time and baseline data were included as fixed effects. Post-hoc comparisons
118 between the three occlusion phases were performed using linear contrasts. The normality of
119 the residues was verified graphically. In case of normality deviation (without possible log
120 transformation), the comparisons between the three occlusion phases were performed using
121 Wilcoxon's signed-rank test. Bilateral tests were performed with a significance level of 5%.
122 Correlations between biomarker serum levels and acidemia parameters during occlusion
123 phases (at all time of measures) were evaluated using linear mixed models by including sheep
124 as a random effect and time as a fixed effect. Statistical analyses were performed using the
125 SAS software (v. 9.4; SAS Institute, Cary, NC, USA).

126 *Ethical approval*

127 The use of anesthesia, surgical procedure, and experimental protocol were consistent with the
128 recommendations of the Ministry of Higher Education and Research. This study was
129 approved by the Animal Experimentation Ethics Committee (Comité d'Ethique en
130 Expérimentation Animale, Avis N°2016121312148878).

131 Results

132 Fourteen ewes were instrumented. Four were excluded from our analysis: two fetuses died in
133 utero at postoperative day 1, one delivery occurred at postoperative day 3 and one occluder
134 ruptured during the first phase of UCO.

135 Ten experiments were performed. Nine ewes had a multiple gestation (Table 1). Five fetuses
136 reached endpoint before the end of the experiment: one during phase B and the other four
137 during phase C.

138 During the baseline control period, all measurements of FHR, mean ABP, and arterial blood
139 gases were in the normal range (Table 2).

140 There was no significant difference between phases A, B, and C for heart rate and mean
141 ABP. There was a significant difference in UCO ABP between phases A and C (54.7 ± 6.2 vs
142 36.1 ± 17.2 , $p = 0.009$) and between phases B and C (47.1 ± 15.1 vs 36.1 ± 17.2 , $p = 0.006$).

143 Partial pressure of oxygen (PaO_2) was not modified while partial pressure of carbon dioxide
144 (PaCO_2) increased significantly between phases A and C ($53 \text{ mmHg} \pm 5.1$ vs $69.9 \text{ mmHg} \pm$
145 16.7 , $p = 0.006$). pH decreased significantly throughout UCO series: 7.29 (7.21 - 7.37) in
146 phase A vs 7.15 (7.02 - 7.28) in phase B vs 6.99 (6.86 - 7.12) in phase C ($p < 0.05$, for all).

147 Lactates increased significantly between the 3 occlusion phases, 5.88 ± 2.35 in phase A vs
148 11.14 ± 3.93 in phase B vs 15.25 ± 1.56 in phase C ($p < 0.05$ for all). Base excess also varied
149 significantly from -1.2 ± 6.3 in phase A to -8.5 ± 7.3 in phase B to -14.8 ± 5 in phase C ($p <$
150 0.05 , for all).

151 Serum levels of fetal S100B increased progressively between phases A and B, $11.5 \mu\text{g} \pm 3.8$
152 vs $12.9 \mu\text{g} \pm 4.4$, $p < 0.001$. We observed a significant difference in fetal S100B serum
153 concentration when compared to baseline period (ΔS100B), with a progressive increase
154 between phases A and B ($7\% \pm 4$ vs $17\% \pm 13$, $p = 0.030$) and between phases A and C (7%
155 ± 4 vs $24\% \pm 8$, $p < 0.001$).

156 Fetal c-TnT serum levels increased during occlusions: 102 ng/L (58-119) in phase A, vs 119
157 ng/L (103-198) in phase B vs 169 ng/L (128-268) in phase C ($p < 0.05$, for all). When
158 compared to the baseline control period, fetal Δ cTnT was significantly modified throughout
159 OCT series: 5.0% (-3; 45) in phase A, 51% (4;263) in phase B, and 77% (56.5; 269) in phase
160 C ($p < 0.05$ for all). There was no difference observed in the maternal S100B and c-TnT
161 dosages throughout the experiment.

162 Finally, we found a significant correlation between differences in biomarker serum levels
163 throughout the experiment and acidemia parameters, such as pH, lactate, and base excess
164 (Table 3).

165 Discussion

166 *Main findings*

167 Fetal hypoxia and its early detection during labor remains a major perinatal challenge. The
168 aim is to reduce perinatal asphyxia and its complications, such as HIE. When reproducing a
169 progressive and severe hypoxemia in near-term fetal sheep, we observed a significant rise in
170 fetal S100B and c-TnT serum levels while pH decreases, and lactates rise.

171 *Interpretation*

172 HIE is defined as the clinical manifestation of impaired neonatal brain function following
173 asphyxia due to an antenatal and/or perinatal adverse event (16). Various criteria (biological,
174 clinical and sometimes electrophysiological) are used to define the severity of the
175 neurological damage, many of them included in Sarnats' original classification (16). HIE
176 pathogenesis is fairly complex and is still not understood fully. During HI insult, different
177 intracellular mechanisms are activated, which in turn lead to focal or diffuse cell damage
178 associated with a significant increase in neurobiomarkers, such as S100B (17). S100B is an
179 acid calcium-binding protein specific to the central nervous system where it appears abundant
180 in Schwann cells, glial cells, and neurons. Recently, a series of studies have found that the
181 evaluation of S100B in different body fluids can help early diagnosis of neonates with
182 perinatal asphyxia complicated with HIE (7). In particular, in cord blood samples at birth,
183 S100B was significantly higher in infants with moderate or severe HIE. Increased
184 concentrations were detected 48-72 hours before any clinical, laboratory, or ultrasound signs
185 of brain damage. To our knowledge, the modification of S100B levels during a labor-like
186 acidosis has not yet been evaluated. In our study, we observed an increase in S100B levels
187 during the different phases of the experiment and this increase seems to be detectable as early
188 as the onset of hypoxia, before pH drops below 7.00. In a different model of fetal hypoxia,
189 Giussani et al. reported that, S100B concentrations increased significantly during acute

190 hypoxemia by 24.9 ± 2.9 % (18). In human studies, the difference in S100B concentrations
191 at birth is statistically significant between neonates with HIE and controls (8,19). The
192 sensitivity of this neurobiomarker could be useful in daily practice as a second-line method
193 for screening fetuses at risk of brain damage. Regarding S100B in maternal blood, an
194 increased concentration has been reported within 3 hours of fetal hypoxic insult. Since no
195 damage was seen in the maternal brain of the animals used, the authors concluded that some
196 of the higher maternal S100B levels were of fetal origin, from across the placental barrier
197 (20). In our study, we did not show any increase in maternal serum levels of S100B in
198 response to severe hypoxia. The possibility of species-specific placental transport of the
199 S100B may explain our differences from the literature.

200 During labor, several adaptive mechanisms such as heart rate decelerations or tachycardia,
201 allow fetuses to withstand hypoxia (21,22). Following a perinatal HI insult, oxygen
202 deprivation causes myocardial damage and neonates develop cardiovascular dysfunction as
203 part of the multiorgan failure showcasing HIE (23,24). The cTnT concentration is higher in
204 newborns developing HIE compared to those who developed no complications (9). In our
205 study, we found that c-TnT increased early as the pH starts to drop below 7.15. These results
206 reinforce the hypothesis of an anaerobic cardiac metabolism secondary to fetal hypoxia.
207 Similarly, Sweetman et al. showed that neonates with severe neonatal hypoxic ischemia have
208 significantly higher serum c-TnT concentrations than other asphyxiated groups (5). Troponin
209 T may be a reliable marker of myocardial injury and may serve as an adjunct for early
210 diagnosis of perinatal asphyxia.

211 *Strengths and limitations*

212 This study provides data on progressive changes in fetal levels of S100B and c-TnT. There is
213 a clinical interest in understanding how these markers behave during the equivalent of a very
214 challenging labor. However, the small number of experiments and important variability of

215 results are obstacles to drawing strong conclusions. The baseline state of our fetuses prior to
216 resuming the experiment was not comparable to previous reports, because PaO₂ was low and
217 lactates elevated. We hypothesized that with the breed used and the high rate of multiple
218 gestation, the fetuses were not comparable to previous studies. The absence of a control
219 group can be discussed, but the biomarker changes were compared to baseline values.
220 Finally, a pH < 6.90 indicated the end of the experiment. Even if models that used pH as a cut
221 off show minimal injury (15,25) compared to those that use hypotension (26), we observed
222 mild to severe hypotension during phase C in our study.

223 Conclusion

224 S100B and c-TnT increased when fetal acidosis occurred, reflecting potential neurological
225 damage and fetal cardiovascular adaptation. It will be interesting to correlate those changes to
226 anatomopathology in a larger sample.

227 Competing interests

228 The authors have no conflicts of interest

229

230 Author contributions

231 Y.H., J.D.P, D.S. and L.G. conducted the experiments. Y.H., J.D.P. and L. L collected all

232 data. Y.H. and C.G. wrote the manuscript. E.D. conducted statistical analysis and wrote the

233 statistics methodology. J.D., P.M., V.H.D. and L.S. reviewed and corrected the manuscript.

234 References

- 235 1. Turner JM, Mitchell MD, Kumar SS. The physiology of intrapartum fetal compromise
236 at term. *Am J Obstet Gynecol.* 2020;222(1):17–26.
- 237 2. Garabedian C, De Jonckheere J, Butruille L, Deruelle P, Storme L, Houfflin-Debarge
238 V. Understanding fetal physiology and second line monitoring during labor. *J Gynecol Obstet
239 Hum Reprod.* 2017 Feb;46(2):113–7.
- 240 3. Lear CA, Wassink G, Westgate JA, Nijhuis JG, Ugwumadu A, Galinsky R, et al. The
241 peripheral chemoreflex: indefatigable guardian of fetal physiological adaptation to labour. *J
242 Physiol.* 2018;596(23):5611–23.
- 243 4. Beharier O, Kahn J, Shusterman E, Sheiner E. S100B - a potential biomarker for early
244 detection of neonatal brain damage following asphyxia. *J Matern-Fetal Neonatal Med Off J
245 Eur Assoc Perinat Med Fed Asia Ocean Perinat Soc Int Soc Perinat Obstet.* 2012
246 Sep;25(9):1523–8.
- 247 5. Sweetman D, Armstrong K, Murphy JFA, Molloy EJ. Cardiac biomarkers in neonatal
248 hypoxic ischaemia. *Acta Paediatr Oslo Nor* 1992. 2012 Apr;101(4):338–43.
- 249 6. Satriano A, Pluchinotta F, Gazzolo F, Serpero L, Gazzolo D. The potentials and
250 limitations of neuro-biomarkers as predictors of outcome in neonates with birth asphyxia.
251 *Early Hum Dev.* 2017 Feb 1;105:63–7.
- 252 7. Gazzolo D, Pluchinotta F, Lapergola G, Franchini S. The Ca²⁺-Binding S100B
253 Protein: An Important Diagnostic and Prognostic Neurobiomarker in Pediatric Laboratory
254 Medicine. *Methods Mol Biol Clifton NJ.* 2019;1929:701–28.
- 255 8. Zaigham M, Lundberg F, Olofsson P. Protein S100B in umbilical cord blood as a
256 potential biomarker of hypoxic-ischemic encephalopathy in asphyxiated newborns. *Early
257 Hum Dev.* 2017;112:48–53.
- 258 9. Jones R, Heep A, Odd D. Biochemical and clinical predictors of hypoxic-ischemic

259 encephalopathy after perinatal asphyxia. *J Matern-Fetal Neonatal Med Off J Eur Assoc*
260 *Perinat Med Fed Asia Ocean Perinat Soc Int Soc Perinat Obstet.* 2018 Mar;31(6):791–6.
261 10. Costa S, Zecca E, De Rosa G, De Luca D, Barbato G, Pardeo M, et al. Is serum
262 troponin T a useful marker of myocardial damage in newborn infants with perinatal
263 asphyxia? *Acta Paediatr Oslo Nor* 1992. 2007 Feb;96(2):181–4.
264 11. Kocylowski RD, Dubiel M, Gudmundsson S, Sieg I, Fritzer E, Alkasi O, et al.
265 Biochemical tissue-specific injury markers of the heart and brain in postpartum cord blood.
266 *Am J Obstet Gynecol.* 2009 Mar;200(3):273.e1-273.e25.
267 12. Garabedian C, Clermont-Hama Y, Sharma D, Aubry E, Butruille L, Deruelle P, et al.
268 Correlation of a new index reflecting the fluctuation of parasympathetic tone and fetal
269 acidosis in an experimental study in a sheep model. *PLOS ONE.* 2018 Jan
270 10;13(1):e0190463.
271 13. Ghesquière L, De Jonckheere J, Drumez E, Sharma D, Aubry E, Deruelle P, et al.
272 Parasympathetic nervous system response to acidosis: evaluation in an experimental fetal
273 sheep model. *Acta Obstet Gynecol Scand.* 2018 Dec 19;
274 14. Vanspranghels R, De Jonckheere J, Drumez E, Lauriot Dit Prevost A, Sharma D,
275 Ghesquiere L, et al. Autonomic response to fetal acidosis using an experimental sheep model.
276 *Eur J Obstet Gynecol Reprod Biol.* 2020 Mar;246:151–5.
277 15. Prout AP, Frasch MG, Veldhuizen RAW, Hammond R, Ross MG, Richardson BS.
278 Systemic and cerebral inflammatory response to umbilical cord occlusions with worsening
279 acidosis in the ovine fetus. *Am J Obstet Gynecol.* 2010 Jan;202(1):82.e1-9.
280 16. Debillon T, Bednarek N, Ego A, LyTONEPAL Writing Group. LyTONEPAL: long
281 term outcome of neonatal hypoxic encephalopathy in the era of neuroprotective treatment
282 with hypothermia: a French population-based cohort. *BMC Pediatr.* 2018 01;18(1):255.
283 17. Lv H, Wang Q, Wu S, Yang L, Ren P, Yang Y, et al. Neonatal hypoxic ischemic

284 encephalopathy-related biomarkers in serum and cerebrospinal fluid. *Clin Chim Acta Int J*
285 *Clin Chem.* 2015 Oct 23;450:282–97.

286 18. Giussani DA, Thakor AS, Frulio R, Gazzolo D. Acute Hypoxia Increases S100 β
287 Protein in Association with Blood Flow Redistribution away from Peripheral Circulations in
288 Fetal Sheep. *Pediatr Res.* 2005 Aug;58(2):179–84.

289 19. Nagdyman N, Kömen W, Ko HK, Müller C, Obladen M. Early biochemical indicators
290 of hypoxic-ischemic encephalopathy after birth asphyxia. *Pediatr Res.* 2001 Apr;49(4):502–
291 6.

292 20. Garnier Y, Frigiola A, Li Volti G, Florio P, Frulio R, Berger R, et al. Increased
293 maternal/fetal blood S100B levels following systemic endotoxin administration and
294 periventricular white matter injury in preterm fetal sheep. *Reprod Sci Thousand Oaks Calif.*
295 2009 Aug;16(8):758–66.

296 21. Vintzileos AM, Smulian JC. Decelerations, tachycardia, and decreased variability:
297 have we overlooked the significance of longitudinal fetal heart rate changes for detecting
298 intrapartum fetal hypoxia? *Am J Obstet Gynecol.* 2016;215(3):261–4.

299 22. Giussani DA. The fetal brain sparing response to hypoxia: physiological mechanisms.
300 *J Physiol.* 2016 Mar 1;594(5):1215–30.

301 23. Polglase GR, Ong T, Hillman NH. Cardiovascular Alterations and Multiorgan
302 Dysfunction After Birth Asphyxia. *Clin Perinatol.* 2016 Sep;43(3):469–83.

303 24. Badurdeen S, Roberts C, Blank D, Miller S, Stojanovska V, Davis P, et al.
304 Haemodynamic Instability and Brain Injury in Neonates Exposed to Hypoxia–Ischaemia.
305 *Brain Sci [Internet].* 2019 Feb 27;9(3).

306 25. Xu A, Matuszewski B, Nygard K, Hammond R, Frasch MG, Richardson BS. Brain
307 Injury and Inflammatory Response to Umbilical Cord Occlusions Is Limited With Worsening
308 Acidosis in the Near-Term Ovine Fetus. *Reprod Sci Thousand Oaks Calif.* 2016;23(7):858–

309 70.

310 26. De Haan HH, Gunn AJ, Williams CE, Gluckman PD. Brief repeated umbilical cord
311 occlusions cause sustained cytotoxic cerebral edema and focal infarcts in near-term fetal
312 lambs. *Pediatr Res.* 1997 Jan;41(1):96–104.

313

Ewes	Number of fetuses	Weight of instrumented fetus	Study terminated due to low pH	Phase
1	2	3805	Yes	C
2	3	2935	No	
3	2	3555	Yes	B
4	2	3850	Yes	C
5	2	3135	No	
6	2	3150	Yes	C
7	2	3380	No	
8	2	3245	Yes	C
9	2	3290	No	
10	1	3125	No	

314

315 **Table 1. Description of our study group**

316 Weights are presented in grams

	Baseline	Umbilical Cord Occlusions Period			p		
	S	A	B	C	A vs B	A vs C	B vs C
FHR (bpm)	183.3 ± 10.6	172.2 ± 16.6	181.3 ± 23.1	176.4 ± 22.5	.17	.79	.45
Mean ABP (mmHg)	47.4 ± 10.8	55.3 ± 10.5	58.1 ± 8.0	59.7 ± 9.3	.35	.35	.52
UCO ABP (mmHg)	-	54.7 ± 6.2	47.1 ± 15.1	36.1 ± 17.2	.15	.009	.006
pH	7.39 ± 0.03	7.29 ± 0.08	7.15 ± 0.13	6.99 ± 0.13	.001	<.001	.002
PaO ₂ (mmHg)	13.6 ± 5.5	14.0 ± 3.8	15.2 ± 2.9	16.3 ± 2.7	.12	.078	.17
PaCO ₂ (mmHg)	46.8 ± 6.2	53.0 ± 5.1	57.2 ± 7.0	69.9 ± 16.7	.002	.006	.013
Base excess (mEq/L)	3.1 ± 4.6	-1.2 ± 6.3	-8.5 ± 7.3	-14.8 ± 5.0	<.001	<.001	<.001
Lactate (mmol/L)	2.51 ± 0.74	5.88 ± 2.35	11.14 ± 3.93	15.25 ± 1.56	<.001	<.001	.008
M S100B (μg/L)	0.44 ± 0.16	0.47 ± 0.14	0.43 ± 0.16	0.45 ± 0.19	.70	.67	.48
M Δ S100B (%)	-	-1.9 ± 2.7	-2.0 ± 5.6	-0.8 ± 0.13	.93	.98	.95
F S100B (μg/L)	10.7 ± 3.4	11.5 ± 3.8	12.7 ± 4.7	12.9 ± 4.4	.032	.001	.14
F Δ S100B (%)	-	7 ± 4	17 ± 13	24 ± 8	.030	<.001	.18
M c-TnT (ng/L) ¹	8 (6 ; 14)	8.5 (6 ; 12)	9 (6 ; 14)	10.5 (6 ; 15)	.75	1	1
M Δ c-Tnt (%)	-	6.3 ± 7.9	3.3 ± 11.5	3.5 ± 15.7	.33	.87	.51
F c-TnT (ng/L) ¹	73 (49 ; 105)	102 (58 ; 119)	119 (103 ; 198)	169 (128 ; 268)	.012	.008	.008
F Δ c-TnT (%) ¹	-	5.0 (-3.0 ; 45.0)	51.0 (4.0 ; 263.0)	77.0 (56.5 ; 269.0)	.012	.008	.008

317 **Table 2. Hemodynamic, blood gas and biochemical measures**

318 Data are presented on average ± standard or median deviation (interquartile range).

319 ¹ P-values were calculated using the Wilcoxon signed-rank test, p < .05 is significant (given in bold)

320 FHR: Fetal Heart Rate, bpm: beats per minutes, ABP: Arterial Blood Pressure, F: Fetal, M: Maternal, cTnT: Cardiac Troponin T; UCO:

321 Umbilical Cord Occlusion

	pH		Lactate		Base excess	
F Δ S100B	-0.049 ± 0.16	0.007	1.271 ± 0.295	<0.001	-2.193 ± 0.559	0.002
F Δ c-TnT	-0.001 ± 0.001	0.034	0.016 ± 0.005	0.004	-0.024 ± 0.009	0.021

322

323 Table 3. Correlations between biomarker serum levels with acidemia parameters.

324 Data are presented on $\beta \pm$ standard error.

325 $p < .05$ is significant (given in bold).

326